-
Posted by
Two Blokes Jun 5 -
Filed in
Stock
-
10 views
HENDERSON, Nevada , June 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q\u00ae Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025), a premier event bringing together leading veterinary professionals and experts from across Asia. The two presentations feature results from two clinical studies conducted by Dr Masahiko Sato, DVM, PhD, DACVIM (SAIM), DAiCVIM (IM) in conjunction with FujiFilm Vet Systems.
